Predictors of long-term progression in the early manifest glaucoma trial
Predictors of long-term progression in the early manifest glaucoma trial
复制标题
DOI：
10.1016/j.ophtha.2007.03.016
复制
发表时间：
2007-11-01
期刊：
影响因子：
13.7
通讯作者：
Yang, Zhongming
中科院分区：
文献类型：
--
作者：
Leske, M. Cristina;Heijl, Anders;Yang, Zhongming
目的：在早期显性青光眼试验（EMGT）结束时，基于所有EMGT患者确定进展因素，并分别评价基线眼压较高和较低的患者设计：临床试验参与者队列。参与者：早期开角型青光眼患者随机接受氩激光小梁成形术加倍他洛尔（n = 129）或不立即治疗（n = 126），方法：考克斯比例风险分析，用风险比（HR）和95%可信区间（Cls）表示。主要结果测量：进展时间，用视野和视盘照相标准定义。结果：随访结束时（中位数，8年），总进展率为67%。治疗使进展风险约减半（HR，0.53; 95% CI，0.39-0.72）;基线IOP较高和较低患者的结果相似（HR，0.41和0.55）。基线进展因素（HR，1.51-2.12; P
Purpose: To determine progression factors at the end of the Early Manifest Glaucoma Trial (EMGT) based on all EMGT patients and evaluate separately patients with higher and lower baseline intraocular pressure (IOP; median split).Design: Cohort of clinical trial participants.Participants: Patients with early open-angle glaucoma randomized to argon laser trabeculoplasty plus betaxolol (n = 129) or no immediate treatment (n = 126), examined every 3 months for up to 11 years.Methods: Cox proportional hazard analyses, expressed by hazard ratios (HRs) and 95% confidence intervals (Cls).Main Outcome Measure: Time to progression, defined by perimetric and photographic disc criteria.Results: Overall progression was 67% when follow-up ended (median, 8 years). Treatment approximately halved progression risk (HR, 0.53; 95% Cl, 0.39-0.72); results were similar for patients with higher and lower baseline IOP (HRs, 0.41 and 0.55). Baseline progression factors (HRs, 1.51-2.12; P